Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

ALTseqTM, a rapid ( 48 hours) whole genome sequencing clinical test for Acute Myeloid Leukemia (AML)

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJonathan J. KeatsYCYeneka CampanaCHC.A. HOLDEN

Discussion

Loading...

Member takes

Overview

ALTseqTM delivers rapid genomic profiling for AML, improving diagnostic and prognostic capabilities in patients.

Key Points

  • This research focuses on developing a rapid whole genome sequencing test for Acute Myeloid Leukemia.
  • Developed ALTseqTM, a rapid whole genome sequencing assay for AML.
  • Samples from peripheral blood or bone marrow are processed within 48 hours.
  • Utilized various algorithms for data analysis and clinical reporting.
  • Achieved an average turnaround time of 35.2 hours for test results.
  • Reported high sensitivity (96%+) for various genomic alterations.
  • Physician satisfaction with the assay was consistently high.

Cite This Study

Keats et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2bchttps://doi.org/10.1182/blood-2025-7036
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 2495: Rapid clinical diagnostic classification and risk stratification in acute myelogenous leukemia (AML) using whole genome sequencing (WGS)2026
  2. 2Rapid diagnosis of acute leukemia with integrated epigenetic and genetic profiling2025 · 2 citations
  3. 3Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients2026
  4. 4Abstract 5300: Clinical utility of whole genome sequencing for upfront risk stratification in AML and MDS patients2026
  5. 5Comprehensive and rapid detection of genomic alterations in pediatric leukemias using whole-genome sequencing with adaptive sampling2025 · 1 citations